MDS 2022 | How can continuous dopaminergic delivery improve outcomes in PD?

Eric Freire-Alvarez, MD, University General Hospital of Elche, Elche, Spain, comments on emerging techniques that enable continuous dopaminergic stimulation. Initial studies assessing levodopa-carbidopa intestinal gel (LCIG) have demonstrated promising efficacy in terms of targeting motor and non-motor symptoms. Increasing infusion from 16 to 24 hours additionally results in control of symptoms throughout the night and into the early morning. Research investigating subcutaneous administration of levodopa is also underway. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.